18553523. CLASSIFICATION OF NEUROLOGICAL OR PSYCHIATRIC DISEASE MANIFESTATIONS USING MULTI-DIMENSIONAL CEREBROSPINAL FLUID ANALYSIS simplified abstract (The Regents of the University of California)
CLASSIFICATION OF NEUROLOGICAL OR PSYCHIATRIC DISEASE MANIFESTATIONS USING MULTI-DIMENSIONAL CEREBROSPINAL FLUID ANALYSIS
Organization Name
The Regents of the University of California
Inventor(s)
[[:Category:Gerd Meyer Zu H�rste of Münster (DE)|Gerd Meyer Zu H�rste of Münster (DE)]][[Category:Gerd Meyer Zu H�rste of Münster (DE)]]
Catharina C. Gross of Münster (DE)
Andreas Schulte-mecklenbeck of Münster (DE)
Sergio E. Baranzini of San Francisco CA (US)
Lohith Madireddy of San Francisco CA (US)
CLASSIFICATION OF NEUROLOGICAL OR PSYCHIATRIC DISEASE MANIFESTATIONS USING MULTI-DIMENSIONAL CEREBROSPINAL FLUID ANALYSIS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18553523 titled 'CLASSIFICATION OF NEUROLOGICAL OR PSYCHIATRIC DISEASE MANIFESTATIONS USING MULTI-DIMENSIONAL CEREBROSPINAL FLUID ANALYSIS
The present invention involves a method for stratifying subjects with neurological or psychiatric disease manifestations, particularly those with neuro-inflammatory autoimmune diseases.
- Determining levels of B cells, immune cells, NKT cells, monocytes, and CD56CD16 NK cells in cerebrospinal fluid and peripheral blood samples.
- Stratifying subjects based on increased B cells, immune cells, decreased NKT cells, monocytes, and CD56CD16 NK cells compared to control samples.
- The combination of these levels indicates whether a subject is suspected to have neuro-inflammatory autoimmune diseases or other neurological/psychiatric conditions.
- Potential Applications:**
This method can be used in clinical settings to accurately diagnose and stratify patients with neurological or psychiatric diseases, particularly neuro-inflammatory autoimmune diseases.
- Problems Solved:**
Provides a more precise and objective way to stratify patients with complex neurological or psychiatric conditions, leading to better treatment decisions and outcomes.
- Benefits:**
Enhances diagnostic accuracy, allows for personalized treatment approaches, and improves patient management in neuro-inflammatory autoimmune diseases and related conditions.
- Commercial Applications:**
This technology has significant commercial potential in healthcare settings, pharmaceutical companies, and research institutions focusing on neurological and psychiatric disorders.
- Prior Art:**
Previous methods for diagnosing and stratifying patients with neurological or psychiatric diseases may lack the specificity and objectivity provided by the present invention.
- Frequently Updated Research:**
Stay updated on the latest research related to neuro-inflammatory autoimmune diseases, diagnostic methods, and treatment strategies to further enhance patient care and outcomes.
- Questions about the Technology:**
1. How does this method compare to traditional diagnostic approaches for neurological and psychiatric diseases? 2. What are the implications of accurately stratifying patients with neuro-inflammatory autoimmune diseases for their treatment and prognosis?
Original Abstract Submitted
The present invention relates to a method of stratifying a subject with neurological or psychiatric disease manifestation, preferably with neuro-inflammatory autoimmune diseases a) determining i) a level of B cells in a test cerebrospinal fluid (CSF) sample obtained from a subject; ii) a level of immune cells per μl in said test CSF sample obtained from said subject; iii) a level of NKT cells in said test CSF sample obtained from said subject; iv) a level of monocytes in said test CSF sample obtained from said subject, and v) a level of CD56CD16 NK cells in a test peripheral blood (PB) sample obtained from said subject, and b) stratifying said subject as suffering from neuro-inflammatory autoimmune diseases, if the following are fulfilled: i) the level of B cells is increased relative to corresponding levels of B cells in control CSF samples obtained from subjects not suffering from neuro-inflammatory autoimmune diseases; ii) the level of immune cells per μl is increased relative to corresponding levels of immune cells per μl in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; iii) the level of NKT cells is decreased relative to corresponding levels of NKT cells in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; iv) the level of monocytes is decreased relative to corresponding levels of monocytes in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; v) the level of CD56CD16 NK cells is decreased relative to corresponding levels of CD56CD16 NK cells in control PB samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases, wherein the combination of said levels i)-v) of step b) is indicative for whether said subject is suspected to suffer from neuro-inflammatory autoimmune diseases or from another neurological or psychiatric disease manifestation other than neuro-inflammatory autoimmune disease. Further, the present invention relates to a data processing system comprising a processor configured to perform the method of the invention, a flow cytometry device capable of detecting the abovementioned levels and a computer program comprising instructions to cause the data processing system or the flow cytometry device to execute the steps of the method of the invention. Finally, the present invention relates to a kit comprising a fluorescently labeled binding partner for certain surface markers used in the method of the invention.
